Moxifloxacin (in the form of hydrochloride)
VIGAMOX contains the active substance moxifloxacin. Moxifloxacin belongs to a class of antibiotics called fluoroquinolones, used to treat bacterial eye infections. VIGAMOX eye drops are used to treat bacterial eye infections (conjunctivitis).
Consult a doctor or pharmacist:
Like any other antibiotic, long-term use of VIGAMOX may lead to the development of other infections.
Tell the doctor or pharmacist about all medicines the patient is taking, including those obtained without a prescription.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult a doctor before using VIGAMOX eye drops.
For a short time after administering VIGAMOX, vision may be blurred. Do not drive or operate machinery until vision returns to normal.
Always use this medicine exactly as the doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
Adults, including the elderly and children: 1 drop into the affected eye(s) 3 times a day (morning, afternoon, and evening). VIGAMOX can be used in children, patients over 65 years old, and patients with kidney and liver diseases. The use of this medicine is not recommended in newborns, as there is only limited information available on its use in these patients. This medicine should be used in both eyes only if advised by a doctor. VIGAMOX is for eye use only. The infection usually clears up within 5 days. If the patient does not notice an improvement, they should contact their doctor. The use of drops should be continued for a further 2-3 days or as long as the doctor advises.
1
2
3
If the drop does not get into the eye, try again.
If more VIGAMOX is used than recommended:rinse the eyes with warm water.
Do not administer more drops until the next normal dose is due.
If VIGAMOX is accidentally swallowed, consult a doctor or pharmacist for advice.
If a dose of VIGAMOX is missed:continue using the medicine, giving the next dose at the scheduled time. Do notgive a double dose to make up for a missed dose.
If the patient is using other eye drops, they should leave a 5-minute interval between administering VIGAMOX and other drops.
Like all medicines, VIGAMOX can cause side effects, although not everybody gets them.
It is usually possible to continue using the drops, unless the side effects are serious or if the patient experiences severe allergic reactions.
inform their doctor immediately:swelling of the hands, feet, ankles, face, lips, mouth, or throat, which may cause difficulty swallowing or breathing, rash or urticaria, large blisters, wounds, or ulcers.
(may affect up to 1 in 10 people)
Eye disorders:eye pain, eye irritation
(may affect up to 1 in 100 people)
Eye disorders:dry eye, eye itching, eye redness, inflammation of the eye surface or scarring, broken blood vessel in the eye, abnormal sensation in the eye, eyelid disorders, itching, redness, or swelling
General disorders:headache, unpleasant taste in the mouth
(may affect up to 1 in 1,000 people)
Eye disorders:corneal disease, blurred or impaired vision, conjunctivitis or eye infection, eye strain, eye swelling
General disorders:vomiting, discomfort in the nose, feeling of lumps in the throat, decreased iron levels in the blood, abnormal liver test results, skin sensation disorders, pain, throat irritation
(frequency cannot be estimated from the available data)
Eye disorders:eye infection, clouding of the eye surface, corneal swelling, deposits on the eye surface, increased eye pressure, scratching on the eye surface, eye allergy, eye discharge, increased tear production, sensitivity to light
General disorders:shortness of breath, irregular heartbeat, dizziness, worsening of allergic symptoms, itching, rash, skin redness, nausea, and urticaria.
If you experience any side effects, including any side effects not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and carton, after "EXP". The expiry date refers to the last day of that month.
There are no special precautions for storage.
The bottle should be discarded 4 weeks after first opening.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The active substance ismoxifloxacin.
One ml of eye drops contains 5 mg of moxifloxacin (as 5.45 mg of moxifloxacin hydrochloride). One drop contains 190 micrograms of moxifloxacin.
The other ingredients are:sodium chloride, boric acid, purified water.
Additionally, small amounts of sodium hydroxide and hydrochloric acid are added to adjust the pH.
The medicine is a liquid (clear, greenish-yellow solution), supplied in cartons containing a 5 ml plastic bottle with a screw cap.
Novartis Poland Sp. z o.o., ul. Marynarska 15, 02-674 Warsaw, tel. +48 22 37 54 888
Siegfried El Masnou, S.A., Camil Fabra 58, El Masnou, 08320 Barcelona, Spain
Novartis Manufacturing NV, Rijksweg 14, 2870 Puurs-Sint-Amands, Belgium
Novartis Farmacéutica, S.A., Gran Via de les Corts Catalanes, 764, 08013 Barcelona, Spain
Novartis Pharma GmbH, Roonstrasse 25, 90429 Nürnberg, Germany
This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
MOXIFLOXACIN ALCON:
Germany
KANAVIG:
Belgium, Luxembourg
VIGAMOX:
Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, Greece, Iceland, Latvia, Lithuania, Malta, Netherlands, Poland, Portugal, Romania, Spain, Slovakia, Slovenia, Sweden, Hungary, Italy
MOXIVIG:
United Kingdom (Northern Ireland)
Date of last revision of the leaflet:11/2024
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.